Se prevé que el mercado de partículas similares a virus (VLP) alcance los 7.858,82 millones de dólares en 2028, frente a los 4.601,84 millones de dólares de 2021; se espera que crezca a una tasa compuesta anual del 7,9% de 2021 a 2028.
La comercialización de vacunas basadas en partículas similares a virus contra virus humanos y animales, vigorosa Las actividades de investigación y desarrollo para el desarrollo de vacunas virales basadas en partículas similares a virus y las partículas similares a virus que emergen como una plataforma de inmunoterapia confiable para enfermedades alérgicas son los factores clave responsables del crecimiento general del mercado. Sin embargo, los desafíos técnicos relacionados con el diseño, la purificación y el almacenamiento de eVLP impiden el crecimiento general del mercado. Además, las complejidades asociadas con la fabricación de vacunas con partículas similares a virus, junto con el exceso de costos y requisitos de tiempo de los procesos (como el procesamiento posterior de vacunas basadas en partículas similares a virus), limitan aún más el crecimiento del mercado global. Además, todavía se están desarrollando terapias basadas en partículas similares a virus destinadas a enfermedades virales tópicas y emergentes, así como al cáncer, lo que plantea oportunidades lucrativas para el crecimiento general del mercado.
Perspectivas estratégicas
Es probable que América del Norte continúe su dominio en el mercado de partículas similares a virus durante 2021-2028. Estados Unidos tiene la mayor participación del mercado en América del Norte y se espera que continúe esta tendencia durante el período previsto. Esto se atribuye principalmente a la susceptibilidad comúnmente observada de las personas a las infecciones virales, como la influenza viral causada por diferentes variantes. Además, las continuas actividades de I+D necesarias para la fabricación de vacunas vivas atenuadas obligan a las empresas biofarmacéuticas a optar por partículas similares a virus, lo que respalda aún más el crecimiento del mercado.
regiones lucrativas para el mercado de partículas similares a virus (VLP)
Perspectivas del mercado
Las vacunas comercializadas basadas en partículas similares a virus impulsan el crecimiento general del mercado
Según un informe publicado por Frontiers Media SA, el primer virus- La vacuna basada en partículas similares fue diseñada para combatir un virus mortal, la hepatitis B, y las vacunas basadas en partículas similares a virus han producido resultados de seguridad prometedores en comparación con las vacunas tradicionales. La primera vacuna comercializada basada en partículas similares a virus fue contra el VHB. Además, las vacunas comerciales anti-VHB, a saber, "Engerix" fabricada por GlaxoSmithKline y "Recombivax HB" fabricada por Merck & Co. fueron aprobados en 1980 y todos eran partículas parecidas a virus. La siguiente vacuna basada en partículas similares a virus disponible comercialmente fue "Gardasil", que fue aprobada en 2006 para prevenir las infecciones por el virus del papiloma humano (VPH). Además, en medicina veterinaria también se utilizan partículas similares a virus. La primera vacuna veterinaria disponible comercialmente basada en partículas similares a virus demostró ser eficaz contra el circovirus porcino tipo 2 (PCV2).
El papel de las partículas similares a virus en el desarrollo de productos de inmunoterapia contra enfermedades alérgicas estimula aún más el crecimiento general del mercado. Las partículas similares a virus se utilizan en el tratamiento de la rinitis alérgica, el asma y las reacciones de los ácaros del polvo. Los factores antes mencionados impulsan exponencialmente el crecimiento del mercado general de partículas similares a virus. Las vacunas con partículas similares a virus han mostrado una respuesta inmune rápida con reacciones cutáneas leves como efectos secundarios.
Información basada en el tipo de producto
Según el tipo de producto, el mercado de partículas similares a virus se segmenta en hepatitis, cáncer/VPH y Gaucher. enfermedad. El segmento de hepatitis representaría una gran cuota de mercado durante 2021-2028. El informe de Frontiers SA señala que el virus de la hepatitis C (VHC) infecta al 2% de la población mundial y es una de las principales causas de enfermedad hepática y trasplante de hígado. Esta amenaza médica puede abordarse parcialmente mediante la introducción de nuevas terapias antivirales. Por ejemplo, una vacuna con una eficacia del 50 al 80%, dirigida a usuarios de drogas intravenosas de alto riesgo, reduce drásticamente la incidencia del VHC entre la población. Por lo tanto, las partículas similares a virus representan una plataforma de administración de vacunas segura y altamente inmunogénica que induce una respuesta inmune adaptativa. Actualmente se encuentran en ensayos clínicos varias vacunas basadas en partículas similares a virus; sin embargo, las vacunas VLP autorizadas para el VHB y el VPH se utilizan desde hace mucho tiempo. Por lo tanto, las vacunas basadas en partículas similares a virus han demostrado su eficacia en relación con características inmunológicas favorables y las convierten en una de las vacunas contra el VHC prometedoras.
Partículas similares a virus (VLP) Mercado, por tipo de producto: 2020 y 2028
Información basada en fuentes
Según la fuente, el mercado de partículas similares a virus (VLP) se segmenta en levaduras, células de insectos, plantas y otros. El segmento de levadura tiene una cuota de mercado considerable y se prevé que continúe una tendencia similar durante el período previsto. Las partículas similares a virus se producen mediante sistemas de expresión heterólogos, que involucran levaduras o baculovirus, así como plantas y bacterias. La seguridad de las vacunas basadas en partículas similares a virus producidas utilizando sistemas de expresión de levadura contribuye al crecimiento del mercado de partículas similares a virus a base de levadura.
Basado en aplicaciones Insights
Por aplicación, el mercado de partículas similares a virus se segmenta en vacunas y terapias. El segmento de vacunas tendría una participación considerable del mercado en 2021 y es probable que también continúe su dominio en el mercado durante el período de pronóstico. La vacunación se considera una de las formas más eficaces de controlar patógenos y prevenir enfermedades, tanto en humanos como en animales. Las vacunas basadas en partículas similares a virus representan uno de los enfoques más atractivos debido a sus propiedades inmunogénicas intrínsecas y su seguridad. Por ejemplo, las partículas similares a virus son antígenos multiméricos no infecciosos que tienen una estructura particulada, adecuada para la inducción de una respuesta inmunitaria humoral y celular segura y eficaz. Además, las vacunas con partículas similares a virus han demostrado su eficacia en el campo veterinario. Las partículas similares a virus están compuestas únicamente por una o más proteínas estructurales sin presencia de genomas de virus nativos y sin capacidad de autorreplicación en las células. Sin embargo, se pueden producir partículas similares a virus que contienen antígenos monovalentes o multivalentes cumpliendo con los requisitos de vigilancia serológica; la utilidad de las vacunas con partículas similares a virus resulta prometedora en el campo veterinario. Un ejemplo de ello es la utilización de vacunas con partículas similares a virus en el marco de las estrategias de vacunación para diferenciar animales infectados de animales vacunados (DIVA) contra enfermedades animales.
Empresas que operan con partículas similares a virus ( VLP) adoptan la estrategia de innovación de productos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca en el mercado global.
Mercado de partículas similares a virus (VLP): por tipo de producto
- Hepatitis
- Cáncer/VPH
- Enfermedad de Gaucher
Partículas similares a virus (VLP) ) Mercado: por fuente
- Levadura
- Insecto Célula
- Planta
- Otros
Virus -Mercado de partículas similares (VLP): por aplicación
- Vacunas
- Terapéuticas
Mercado de partículas similares a virus (VLP): por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Oriente Medio y África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- América del Sur y Central (SCAM )
- Brasil
- Argentina
- Resto de ESTAFA
Perfiles de empresas
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global virus-like particles (VLP's) market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for virus-like particles (VLP’s). The US is estimated to hold the largest share in the virus-like particles (VLP’s) market during the forecast period. Presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for VLP’s accounting fastest growth of the region during the coming years.
Answer: - Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc. are among the leading companies operating in the global Virus-Like Particles (VLP's) market
The vaccine segment dominated the global virus-like particles (VLP's) market and accounted for the largest revenue of 4,558.08 Mn in 2021.
Based on product-type, hepatitis segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
American Society for Microbiology defines virus-like particles (VLP's) as non-infectious multiprotein structure that are engineered to self-assemble from viral structure proteins. VLP technology proves to be a very powerful tool involved in development of vaccines. Several VLP based vaccines exist in the global market involving hepatitis B virus and human papillomavirus.
Commercial VLP based vaccines against human and animal viruses, intensive research and development activities for the development of VLPs based vaccines effective against viral infections, and VLPs acting as the best immunotherapy platform for allergic diseases are the key driving factors responsible for the overall market growth.
The List of Companies - Virus-like Particles (VLP's) Market
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Nov 2021
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2021
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Nov 2021
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Nov 2021
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Nov 2021
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)